Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06592326
PHASE3

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a randomized, controlled, open-label, multicenter phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of 9MW2821 combined with Toripalimab versus standard chemotherapy in first-line locally advanced or metastatic urothelial cancer.

Official title: A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

460

Start Date

2024-08-22

Completion Date

2028-12

Last Updated

2024-09-19

Healthy Volunteers

No

Interventions

DRUG

9MW2821

9MW2821, 1.25mg/kg, intravenous (IV) infusion

DRUG

Toripalimab

Toripalimab, 240mg, intravenous (IV) infusion

DRUG

Gemcitabine

Gemcitabine: 1000mg/m2, intravenous (IV) infusion

DRUG

Cisplatin/Carboplatin

Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China